Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2020 | CARCIK-CD19: allogeneic and non-viral CAR T-cells

Chiara Magnani • 30 Jan 2020
CAR-T Meeting 2020
Acute Lymphoblastic Leukemia Leukemia CAR-T

Chiara Magnani, PhD, University of Milano-Bicocca, Milan, Italy & Fondazione Tettamanti, Monza Italy, discusses the ongoing phase I/II trial on donor-derived CD19 CAR cytokine-induced killer (CIK) cells engineered with a sleeping beauty (SB) transposon for relapsed B-cell acute lymphoblastic leukemia (B-ALL). Dr Magnani outlines the manufacturing process and reveals that SB-engineered CARCIK-CD19 cells can expand and persist in pediatric and adult B-ALL patients who have relapsed after hematopoietic stem cell transplantation (HSCT). This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.

More from Chiara Magnani

2:15
CAR T-cell therapy: the importance of donor-derived cells in treatment
Chiara Magnani • 16 Dec 2021
4:22
CARCIK trial updates: using SB-engineered CAR-T cells in patients with B-ALL
Chiara Magnani • 16 Dec 2021
2:35
What is on the CAR-T horizon?
Chiara Magnani • 11 Dec 2020
5:35
Transposon-manipulated allogeneic CAR-T therapy for B-ALL
Chiara Magnani • 11 Dec 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals